Checkpoint Therapeutics

79 articles about Checkpoint Therapeutics

• Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

  3/22/2024

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

• Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

  3/18/2024

  Checkpoint Therapeutics, Inc. today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.

• Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

  1/29/2024

  Checkpoint Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 7,756,233 shares of its common stock.

• Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

  1/11/2024

  Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.

• U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

  12/18/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or radiation.

• Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

  12/5/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT) today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC”), through the administration of cosibelimab.

• Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

  11/13/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights.

• Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

  10/18/2023

  Checkpoint Therapeutics, Inc. today announced the publication of results from the multicenter, multiregional, pivotal trial evaluating cosibelimab, a differentiated and potential best-in-class anti-PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma (“cSCC”), in the Journal for ImmunoTherapy of Cancer (JITC).

• Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

  10/2/2023

  Checkpoint Therapeutics, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock.

• Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

  9/21/2023

  Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City.

• Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET.

• Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

  8/14/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2023, and recent corporate highlights.

• Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

  7/31/2023

  Checkpoint Therapeutics, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock.

• Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

  7/27/2023

  Checkpoint Therapeutics, Inc. today announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”).

• Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

  6/28/2023

  Checkpoint Therapeutics, Inc. today announced that new pharmacokinetic (“PK”) modeling data on cosibelimab supporting the extension to an every-three-week dosing regimen were presented today at the Population Approach Group Europe (“PAGE”) 2023 annual meeting, taking place in A Coruña, Spain.

• Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  5/23/2023

  Checkpoint Therapeutics, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock.

• Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

  5/15/2023

  Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the first quarter ended March 31, 2023, and recent corporate highlights.

• Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

  3/31/2023

  Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2022, and recent corporate highlights.

• Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

  3/2/2023

  Checkpoint Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing the Biologics License Application (“BLA”) for cosibelimab.

• Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

  1/17/2023

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST.